<DOC>
	<DOCNO>NCT02375022</DOCNO>
	<brief_summary>This single-arm pilot study try invesitgate well give icotinib rh-endostatin ( EndostarÂ® ) work treat patient advanced stage non-small cell lung cancer ( NSCLC ) epidermal growth factor receptor ( EGFR ) activate mutation . Icotinib may stop growth tumor cell block enzymes need cell growth . Anti-angiogeneiss drug , rh-endostatin , block tumor growth inhibit ability tumor grow new blood vessel spread . It yet know whether icotinib effective give rh-endostatin NSCLC patient EGFR activate mutation .</brief_summary>
	<brief_title>Rh-Endostatin Combination With Icotinib Advanced NSCLC With EGFR Mutations</brief_title>
	<detailed_description>1 . Open-label , single-arm , prospective pilot study . 2 . Definition advance non small cell lung cancer : stage IIIb IV . EGFR mutation status : activating mutation ( define deletion 19 exon 21 L858R mutation ) . 3 . Before start study treatment , compute tomography scan chest , B ultrasound abdomen , 12-lead electrocardiogram , MRI scan brain , bone scan require . 4 . Tumor response , base investigator-assessed Response Evaluation Criteria Solid Tumors ( RECIST v.1.1 ) , evaluate every 6 week treatment . 5 . Exploratory evaluation perform use dynamic contrast enhance MRI ( DCE-MRI ) . 6 . QoL assess use core module , complete patient baseline cycle treatment . 7 . All patient prematurely discontinue treatment reason follow survival .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Histologic documentation non small cell lung cancer , activate epidermal growth factor receptor ( define deletion 19 exon 21 L858R mutation ) . Stage IV disease accord 7th Edition American Joint Committee Cancer stag system Measureable disease Life expectancy &gt; = 12 month Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 Absolute neutrophil count ( ANC ) &gt; = 1 , 500/mm^3 , platelet count &gt; = 100,000/mm^3 , hemoglobin &gt; = 9.0 g/dL . Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) , serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamic pyruvic transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) = &lt; 2.5 x ULN patient without liver bone metastasis ; &lt; 5 x ULN patient liver bone metastasis , cockcroftGault calculate creatinine clearance &gt; = 45 ml/min creatinine = &lt; 1.5 x ULN . Prothrombin time ( PT ) = &lt; 1.5 x ULN , partial thromboplastin time ( PTT ) = &lt; ULN Urine dipstick proteinuria &lt; 2+ . Patients discover &gt; = 2 + proteinuria dipstick urinalysis baseline undergo 24hour urine collection must demonstrate &lt; 1 g protein 24 hour . Negative pregnancy test do = &lt; 7 day prior randomization , woman childbearing potential . Provide inform write consent . Willing return enrol institution followup . Willing provide tissue blood sample correlative research purpose . Evidence bleed diathesis coagulopathy . Evidence central nervous system involvement brain metastasis confirm head CT brain MRI within 28 day prior register protocol therapy . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior registration protocol therapy . Anticipation need major surgical procedure course study . Minor surgical procedure fine needle aspiration core biopsy within 7 day prior registration protocol therapy . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior registration protocol therapy . Serious , nonhealing wound , ulcer , bone fracture . History hemoptysis . Clinically significant infection judge treat investigator . Other active malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>